(2R)-2-ethylchromane-2-carboxylic acids: Discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 3255-3263

  Koyama, Hiroo ^a   Miller, Daniel J ^a   Boueres, Julia K ^a   Desai, Ranjit C ^a   Jones, A Brian ^a   Berger, Joel P ^a   MacNaul, Karen L ^a   Kelly, Linda J ^a   Doebber, Thomas W ^a   Wu, Margaret S ^a   Zhou, Gaochao ^a   Wang, Pei Ran ^a   Ippolito, Marc C ^a   Chao, Yu Sheng ^a   Agrawal, Arun K ^b   Franklin, Ronald ^b   Heck, James V ^a   Wright, Samuel D ^a   Moller, David E ^a   Sahoo, Soumya P ^a  

^a Department of Medicinal Chemistry ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLCHROMANE 2 CARBOXYLIC ACID DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RHESUS MONKEY; STRUCTURE ACTIVITY RELATION; SYRIAN HAMSTER;

ANIMALS; ANTILIPEMIC AGENTS; BENZOPYRANS; CHROMANS; CRICETINAE; DIABETES MELLITUS, TYPE 2; DOGS; HUMANS; HYPOGLYCEMIC AGENTS; MACACA MULATTA; MALE; MESOCRICETUS; MICE; PHENYL ETHERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 2542612265     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030621d     Document Type: Article

References (52)

1. Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414, 821-827.
2. Saltiel, A. R. New perspective into the molecular pathogenesis and treatment of type 2 Diabetes. Cell 2001, 104, 517-529.
3. Cobb, J.; Dukes, L. Recent advances in the development of agents for the treatment of type 2 diabetes. Annu. Rep. Med. Chem. 1998, 33, 213-222.
4. American Diabetes Association. Economic cost of diabetes in the U.S. in 2002. Diabetes Care 2003, 26, 917-932.
5. Hulin, B.; McCarthy, P. A.; Gibbs, E. M. The glitazone family of antidiabetic agents. Curr. Pharm. Des. 1996, 2, 85-102.
6. Combs, T. P.; Wagner, J. A.; Berger, J. P.; Doebber, T. W.; Wang, W. J.; Zhang, B. B.; Tanem, M.; Berg, A. H.; O'Rahilly, S.; Savage, D. B.; Chatterjee, K.; Weiss, S.; Larson, P. J.; Gottesdiener, K. M.; Gertz, B. J.; Charron, M. J. ; Scherer, P. E.; Moller, D. E. Induction of adipocyte complement-related protein of 30 kDa by PPARgamma agonists: A potential mechanism of insulin sensitization. Endocrinology 2002, 143, 998-1007.
7. Ibrahimi, A.; Teboul, L.; Gaillard, D.; Amri, E. Z.; Ailhaud, G.; Young, P.; Cawthorne, M. A.; Grimaldi, P. A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 1994, 46, 1070-1070.
8. Tontonoz, P.; Hu, E.; Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor. Cell 1994, 79, 1147-1156.
9. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkinson, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.
10. Willson, T. M.; Brown, P. T.; Sternbach, D. D.; Henke, B. R. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-550.
11. Berger, J. P.; Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
12. Francis, G. A.; Fayard, E.; Picard, F.; Auwerx, J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 2003, 65, 261-311.
13. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature 2000, 405, 421-424.
14. Desvergne, B.; Wahli, W. Peroxisome Proliferator-Activated Receptors: Nuclear control of metabolism. Endocr. Rev. 1999, 20, 649-688.
15. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
16. Auwerx, J. PPARγ, the ultimate thrifty gene. Diabetolotgia 1999, 42, 1033-1049.
17. Martin, G.; Schoonjans, K.; Staels, B.; Auwerx, J. PPAR activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998, 137 (Suppl.), S75-S80.
18. Ginsberg, H. N.; Stalenhoef, A. F. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J. Cardiovasc. Risk 2003, 10, 121-128.
19. Zimmet, P.; Alberti, K. G. M. M.; Shaw, J. Global and societal implication of the diabetes epidemic. Nature 2001, 414, 782-787.
20. Executive summary of the third report of the National Cholesterol Education Program Expert Panel of detection, evaluation, and treatment of high blood cholesterol in adults. J. Am. Med. Assoc. 2001, 285, 2486-2496.
21. American Diabetes Association. Detection and management of lipid disorders in diabetes. Diabetes Care 1993, 16, 828-834.
22. American Diabetes Association. Position Statement: Management of dyslipidemia in adults with diabetes. Diabetes Care 1998, 21 (Suppl. 1), 160-178.
23. Davis, P. H.; Dambrosia, J. M.; Shoenberg, B. S. Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann. Neurol. 1987, 22, 319-327.
24. Garg, A.; Grundy, S. M. Diabetic dyslipidemia and its therapy. Diabetes Rev. 1997, 5, 425-433.
25. Garg, A.; Grundy, S. M. Treatment of dyslipidemia in patients with noninsulin-dependent diabetes mellitus. Diabetes 1995, 3, 433-445.
26. Howard, B. V.; Howard, W. J. Dyslipidemia in noninsulin-dependent diabetes mellitus. Endocrinol. Rev. 1994, 15, 263-274.
27. Rubins, H. B.; Robins, S. J.; Collins, D.; Fye, C. L.; Anderson, J. W.; Elam, M. B.; Faas, F. H.; Linares, E.; Shaefer, E. J.; Shectman, G.; Wilt, T. J.; Wittes, J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low level of high-density lipoprotein cholesterol. N. Engl. J. Med. 1999, 341, 410-418.
28. Robins, S. J.; Collins, D.; Wittes, J. T.; Papademetrious, V.; Deedwania, P.; Schaefer, E.; McNamara, J. R.; Kashyap, M. L.; Hershman, J. M.; Wexler, L. F.; Rubins, H. B. Relation of gemfibrozil treatment and lipid levels with major coronary events. J. Am. Med. Assoc. 2001, 285, 1585-1591.
29. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001, 357, 905-910.
30. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-Substituted Benzyl)-thiazolidine diones as structurally new antihyperglycemic Agents. Bioorg. Med. Chem. Lett. 1999, 9, 533-538.
31. Auwerx, J. Altered fatty acid partitioning by PPAR activators improves glucose homeostasis: A case for PPARα and γ coagonists. Insulin Resist., Metab. Dis. Diabetic Complications 1999, 167-172.
32. Oplinger, J.; Spearing, P.; Collins, J.; Dezube, M.; Plunket, K.; Lewis, M.; Oliver, W., Jr.; Tong, T.; Alva, G. Discovery of Potent PPARα and PPARγ Dual Agonists; Presented at the American Chemical Society Annual Meeting, San Diego, March 2001; poster MEDI 238.
33. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjoblom, K.; Karlsson, U.; Lindstedt, E.-L.; Bamberg, K. Structure of the PPARα and -γ ligand binding domain in complex with AZ 242: Ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9, 699-706.
34. Cheng, P. T.; Chandrasena, G.; Chen, S. BMS-298585 is a novel, uniquely balanced dual activator of peroxisome proliferator-activated receptors (PPAR) alpha and gamma, with an excellent ADME profile. Diabetes 2002, 51 (Suppl. 2), A94.
35. Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V. S. R.; Rajagopalan, R. (-)3-[4-[2-Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid-[(-)DRF2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 2001, 44, 2675-2678.
36. Brooks, D. A.; Etgen, G. J.; Rito, C. J.; Shuker, A. J.; Dominianni, S. J.; Warshawsky, A. W.; Ardecky, R.; Paterniti, J. R.; Tyhonas, J.; Broderick, C. L.; Oldham, B. A.; Montrose-Rafizadeh, C.; Winneroski, L. L.; Faul, M. M.; McCarthy, J. R. Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]-phenoxy}propionic acids: A new class of dual PPARα/γ agonists. J. Med. Chem. 2001, 44, 2061-2064.
37. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Morgensen, J. P.; Wassermann, K.; Brand, C. L.; Sturis, J.; Woldike, H. F.; Fleckner, J.; Andersen, A. T.; Mortensen, S. B.; Svensson, I. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z.; Sindelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. Novel tricyclic-α-alkoxyphenylpropionic acids: Dual PPARα/γ agonists with hypolipidemic and antidiabetic Activity. J. Med. Chem. 2002, 45, 789-804.
38. Desai, R. C.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Leung, K.; Moller, D. E.; Heck J. V.; Sahoo, S. P. 5-Arylthiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents. Bioorg. Med. Chem. Lett. 2003, 13, 2795-2789.
39. Adams, A. D.; Hu, Z.; von Langen, D.; Dadiz, A.; Elbrecht, A.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Meurer, R.; Forrest, M. J.; Moller, D. E. ; Jones, A. B. O-Arylmandelic acids as highly selective human PPARα/γ agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3185-3190.
40. Miller, A. R.; Etgen, G. J. Novel peroxisome proliferators-activated receptor ligands for type 2 diabetes and the metabolic syndrome. Exp. Opin. Invest. Drugs 2003, 12 (9), 1439.
41. Parks, D. K.; Tomkinson, N. C. O.; Villeneuve, M. S.; Blanchard, S. G.; Willson, T. M. Differential activity of rosiglitazone enantiomers at PPARγ. Bioorg. Med. Chem. Lett. 1998, 8, 3657-3658.
42. Sohda, T.; Mizuno, K.; Kawamatsu, Y. Studies on antidiabetic agents. VI. Asymmetric transformation of (± )-5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4-thiazolidinedione(ciglitazone) with optically active benzylamines. Chem. Pharm. Bull. 1984, 32, 4460-4465.
43. Witiak, D. T.; Stratford, E. S.; Nazareth, R.; Wagner, G.; Feller, D. R. 6-Chlorochroman-2-carboxylic acids: Synthesis and biological evaluation as antagonists for cholesterol biosynthesis and lipolysis in vitro. J. Med. Chem. 1971, 14, 758-766.
44. Loiodice, F.; Longo, A.; Bianco, P.; Tortorella, V. 6-Chloro-2,3-dihydro-4H-1-benzopyran carboxylic acids: Synthesis, optical resolution and absolute configuration. Tetrahedron Asymmetry 1995, 6, 1001-1011.
45. Barker, G.; Ellis, G. P. Benzopyranones. Part I. 6-Amino, and 6-hydroxy-2-substituted chromone. J. Chem. Soc. C, 1970, 2230.
46. Shitara, H.; Aoki, Y.; Nohira, H. Synthesis of optically active 2-methylchroman derivatives and application to chiral dopants for nematic liquid crystals. Bull. Chem. Soc. Jpn. 2000, 73, 259.
47. Fitton, A. O.; Hatton, B. T. Pharmacologically active 4-oxo-4H-chromen-2-carboxylic acids. Part 11. The synthesis of 4-oxo-4H-chromene-2-carboxylic acids containing a fused imidazole or oxazole ring. J. Chem. Soc. C 1970, 2518.
48. U.S. Patent 6,090,836, July 18, 2000.
49. U.S. Patent 6,008,237, December 28, 1999.
50. U.S. Patent 6,090,839, July 18, 2000.
51. Berger, J. P.; Petro, A. E.; MacNaul, K. L.; Kelly, L. J.; Zhang, B. B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanem, M. R.; Thompson, M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol. Endocrinol. 2003, 17, 662-676.
52. Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M.; Berger, G. D.; Mosley, R.; Marquis, R. W.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E. Novel peroxisome proliferator-activated receptor PPARγ and PPARδ ligands produce distinct biological effects. J. Biol. Chem. 1999, 274, 6718-6725.